Navigation Links
Lilly Declares Second-Quarter Dividend
Date:4/21/2008

INDIANAPOLIS, April 21 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the second quarter of 2008 of $0.47 a share on outstanding common stock. This is the same dividend as was paid in the first quarter and maintains the annual indicated dividend rate for 2008 of $1.88 per share.

The dividend is payable June 10, 2008, to shareholders of record at the close of business on May 15, 2008.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com . F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lilly to Streamline Indianapolis Manufacturing and Engineering Operations
2. Lilly Adjusts Time of Conference Call for First Quarter 2008 Financial Results Announcement
3. Lilly Sets Date and Conference Call for First Quarter 2008 Financial Results Announcement
4. State of Alaska and Eli Lilly and Company Reach Agreement to Settle Zyprexa Lawsuit
5. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
6. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
7. Newly Labeled Therapies for Neuropathic Pain, Including Drugs From Pfizer and Eli Lilly, Will Drive Growth in the Chronic Pain Drug Market
8. Mental Health Parity Laudable, But House Legislation Would Put Medicaid Patients at Risk, Lilly Says
9. FDA Issues Not-Approvable Letter for Lillys Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
11. Michael L. Eskew Elected to Lilly Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... a year and a half of planning the Multiple Pathways of Recovery Conference , ... Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & ... explore the many pathways individuals use to get into and sustain their recovery. Pathways ...
(Date:5/27/2016)... ... 2016 , ... More than a third of American adults are considered obese, ... has received increased attention in recent years, as an article published May ... loss, most people are familiar with the basic requirements of maintaining a healthy diet ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue ... Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in ... Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon ...
(Date:5/27/2016)... ... ... An influential resource amongst nurses and professionals in the health care world, ... of topics detailing why we appreciate nurses in so many different ways. From exclusive ... being in a major recession to one of the hottest growing professions in any ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to ... which we as a society can control and change. , As nearly 795,000 Americans ... 40 seconds within the United States. Plus, with an estimated 129,000 of these people ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today ... test for wounds and infections. This test ensures ... and select viruses. The test requires only a ... David G. Bostwick , MD, ... to facilitate wound healing: "We are excited to ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology: